Levosulpiride versus pimozide in negative symptoms of schizophrenia

Current Therapeutic Research - Clinical and Experimental

Volumn 57, Issue 10, 1996, Pages 797-809

  De Ronchi, Diana ^a   Ruggeri, Mirella ^a   Belelli, Gabriella ^a   Volterra, Vittorio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; PIMOZIDE; SULPIRIDE;

ADULT; ARTICLE; AUTONOMIC DYSFUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; ENDOCRINE DISEASE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; INSOMNIA; LABORATORY TEST; MALE; NEGATIVE SYNDROME; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SINGLE BLIND PROCEDURE;

EID: 0029853243     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(96)80085-3     Document Type: Article

References (37)

1. Stanley M, Rotrosen J. The benzamides. Pharmacology, neurobiology and clinical aspects. In: Advances in Biochemical Psychopharmacology, Vol. 35, New York: Raven Press; 1982:7-15.
2. Forgione A, Spano PF, Zanoboni Muciaccia W, Marmo E. Neuropsicofarmacologia e clinica della I-Sulpiride. Farmaci. 1990;14:95-112.
3. Rossi F, Forgione A. Pharmacotoxicological aspects of levosulpiride. Pharmacol Res. 1995;31:81-94.
4. Wolf ME, Roth RH. Dopamine autoreceptors. In: Creese I, Fraser CM, eds. Dopamine Receptors. New York: Alan R. Liss Inc; 1987:45-96.
5. Jenner P, Marsden CD. The mode of action of sulpiride as an atypical antidepressant agent. In: Costa E, Racagni G, eds. Typical and Atypical Antidepressants: Clinical Practice. New York: Raven Press; 1982:85-103.
6. Forgione A. Levo-sulpiride. Drug Fut. 1987;12:944-949.
7. Silverstone T, Cookson J, Ball R, et al. The relationship of dopamine receptor blockade to clinical response in schizophrenic patients treated with pimozide or haloperidol. J Psychiatr Res. 1984;18:255-268.
8. The Scottish Schizophrenia Research Group: The Scottish first episode schizophrenia study II. Treatment: Pimozide versus flupenthixol. Br J Psychiatry. 1987;150:334-338.
9. Des Lauriers A, Baruch P, Ammar S, et al. Use of pimozide as single drug therapy in a daily dose of 1 mg in chronic hallucinatory psychosis. Ann Psychiatr. 1990;5:270-271.
10. Dahl SG. Classification of neuroleptic drugs - lack of effect on negative symptoms in schizophrenia. Psychiatr Psychobiol. 1987;2:289-296.
11. Opler LA, et al. The role of pimozide in clinical psychiatry: A review. J Clin Psychiatry. 1991;52:221-233.
12. Weizman A, Maoz B, Treves I, et al. Sulpiride-induced hyperprolactinemia and impotence in male psychiatric outpatients. Progr Neuropsychopharmacol Biol Psychiatry. 1985;9: 193-198.
13. Soni SD, Mallik A, Schiff AA. Sulpiride in negative schizophrenia: A placebo-controlled double-blind assessment. Hum Psychopharmacol. 1990;5:233-238.
14. Cassano GB, Castrogiovanni P, Conti L, Bonollo L. Sulpiride versus haloperidol in schizophrenia: A double-blind comparative trial. Curr Ther Res. 1975;17:189-201.
15. Rao VAR, Bailey J, Mirkin A, Coppen A. A clinical and pharmacodynamic evaluation of sulpiride. Psychopharmacology. 1980;80:73-77.
16. Gerlack J, Behnke K, Heltberg J, et al. Sulpiride and haloperidol in schizophrenia: A double-blind cross-over study of therapeutic effect, side effects and plasma concentration. Br J Psychiatry. 1985;147:283-288.
17. Nishikawa T, Tanaka M, Tsuda A, et al. Prophylactic effects of neuroleptics in symptomfree schizophrenics: A comparative dose-response study of timiperone and sulpiride. Biol Psychiatry. 1989;25:861-866.
18. Bratfos O, Haug JO. Comparison of sulpiride and chlorpromazine in psychoses. Acta Psychiatr Scand. 1979;135:164-173.
19. Ishimaru T, Kubo S, Ishikawa H, et al. Clinical evaluation on therapeutic effects of sulpiride, a neuroleptic drug, on schizophrenia by double-blind controlled test. Hiroshima J Med Sci. 1971;19:131-154.
20. Asada S, Ishimaru T, Kubo S, et al. Etude des effets cliniques du sulpiride et de la perphenazine chez 82 schizophrenes par la methode du double aveugle. Encephale. 1976; 2:73-83.
21. Lepola U, Koskinen T, Rimon R, et al. Sulpiride and perphenazine in schizophrenia: A double-blind clinical trial. Acta Psychiatr Scand. 1989;80:92-96.
22. Edwards JG, Alexander JR, Alexander MS, et al. Controlled trial of sulpiride in chronic schizophrenic patients. Br J Psychiatry. 1980;137:522-529.
23. Elizur A, Davidson S. The evaluation of the anti-autistic activity of sulpiride. Curr Ther Res. 1975;18:578-584.
24. Niskanen P, Tamminen T, Viukari M. Sulpiride versus amitriptyline in the treatment of depression. Curr Ther Res. 1975;17:281-284.
25. Harnryd C, Bjerkenstedt L, Bjork K, et al. Clinical evaluation of sulpiride in schizophrenic patients - a double-blind comparison with chlorpromazine. Acta Psychiatr Scand. 1984;11(Suppl 3):7-30.
26. Petit M, Zann M, Lesieur P, Colonna L. The effect of sulpiride on negative symptoms of schizophrenia. Br J Psychiatry. 1987;150:270-271.
27. Catapano F, Maj M, Grimaldi F, et al. Efficacy of low vs. high doses of levosulpiride on negative symptoms of schizophrenia. Pharmacopsychiatry. 1992;25:166. Letter.
28. Mucci A, Nolfe G, Maj M. Levosulpiride: A review of its clinical use in psychiatry. Pharmacol Res. 1995;31:95-101.
29. Mauri MC, Leva P, Coppola MT, Altamura CA. L-Sulpiride in young and elderly negative schizophrenics: Clinical and pharmacokinetic variables. Prog Neuro-Psychopharmacol Biol Psychiatr. 1994;18:355-366.
30. Caley CF, Weber SS. Sulpiride: An antipsychotic with selective dopaminergic antagonist properties. Ann Pharmacother. 1995;29:152-160.
31. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed, revised. Washington, DC: American Psychiatric Association; 1987.
32. Andreasen NC. Negative vs. positive schizophrenia: Definition and validation. Arch Gen Psychiatry. 1982;39:789-794.
33. Andreasen NC. Positive vs. negative schizophrenia: A critical evaluation. Schizophr Bull. 1985;11:380-383.
34. Guy W. Early Clinical Drug Evaluation Unit (ECDEU). Assessment Manual for Psychopharmacology. Rockville, Md: National Institute of Mental Health; 1976.
35. Norusis MJ. SPSS/PC+ Advanced Statistics. Chicago: SPSS Inc; 1988.
36. Alfredsson G, Harnryd C, Wiesel FA. Effects of sulpiride and chlorpromazine on autistic and positive symptoms in schizophrenic patients - relationship to drug concentrations. Psychopharmacology. 1985;85:8-13.
37. Munk-Andersen E, Behnke KI, Heltberg J, et al. Sulpiride versus haloperidol, a clinical trial in schizophrenia. A preliminary report. Acta Psychiatr Scand. 1984;69(Suppl): 31-41.